The Vanguard Group Discloses Position in Mural Oncology

The Vanguard Group, Inc. has released a Form 8.3 as part of the Irish Takeover Panel's disclosure requirements, detailing its position regarding Mural Oncology plc. As of June 16, 2025, Vanguard holds a 4.48% interest in Mural Oncology, translating to 773,059 ordinary shares. There are no disclosed short positions or engagement in cash or stock-settled derivatives. The form confirms no other parties are involved, and no additional agreements or arrangements exist. The recent acquisition involved 16 ordinary shares at a price of 2.45 USD each.

The disclosure aligns with Rules from the Takeover Panel Act, reflecting Vanguard's compliance with regulatory obligations associated with its stake exceeding 1% in Mural Oncology. This statement offers transparency concerning Vanguard's investment activities and interests, ensuring compliance with Irish regulatory standards on disclosures.